Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
4actual
Sites
19
Countries
France, Germany, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Strategic considerations
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-11-05 | actual | When the study began enrolling |
| Primary completion | 2025-05-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-05 | actual | The whole study's end, after follow-up |
| First posted | 2020-09-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: Eftozanermin alfa — also filed as ABBV-621
- Drug: Bortezomib
- Drug: Dexamethasone
Primary outcomes
what the primary-completion date above is the date OFRecommended Phase 2 Dose (RP2D) of Eftozanermin Alfa in Combination With Bortezomib and Dexamethasone (Safety Lead-In Arm)
measured Up to approximately 3 weeks after the first dose of study drug
Objective Response Rate (ORR) (Dose Expansion Arm)
measured Up to approximately 44 weeks after the first dose of study drug
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed